<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03005678</url>
  </required_header>
  <id_info>
    <org_study_id>CREC/16</org_study_id>
    <nct_id>NCT03005678</nct_id>
  </id_info>
  <brief_title>Denosumab Versus Bisphosphonates (Alendronate) in GIOP</brief_title>
  <official_title>Denosumab Versus Oral Bisphosphonate (Alendronate) for Osteoporosis in Long-term Glucocorticoid Users: an Open Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tuen Mun Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tuen Mun Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled trial to compare for the efficacy and tolerability of denosumab and
      oral alendronate in the management of glucocorticoid induced osteoporosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: an open-label randomized controlled trial Duration of study: 12 months

      Treatment arms:

        1. Denosumab: a total of 2 doses in a period of 12 months

        2. Oral alendronate: weekly dose in a period of 12 months Target sample size: 220 patients
           (110 patients in each arm)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bone mineral density at lumbar spine</measure>
    <time_frame>month 12</time_frame>
    <description>BMD lumbar spine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bone mineral density at the hip</measure>
    <time_frame>month 12</time_frame>
    <description>BMD hip</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone turnover markers</measure>
    <time_frame>month 12</time_frame>
    <description>P1NP and osteocalcin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>month 12</time_frame>
    <description>adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>denosumab subcutaneous 60mg every 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alendronate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>alendronate 70mg orally every week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>active treatment group</description>
    <arm_group_label>Denosumab</arm_group_label>
    <other_name>prolia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>comparator</description>
    <arm_group_label>Alendronate</arm_group_label>
    <other_name>fosamax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults (women or men) &gt;18 years of age

          2. Receiving long-term prednisolone treatment for various medical illnesses, defined as a
             daily prednisolone dose of ≥2.5mg/day for ≥12 months).

          3. Informed consent from patients.

          4. Willing to comply with all study procedures

        Exclusion Criteria:

          1. Patients with previous use of denosumab, teriparatide, intravenous bisphosphonates,
             strontium or other experimental anti-osteoporotic agents.

          2. Premenopausal women who plan for pregnancy within 18 months of study entry.

          3. Patients with known bone disorders such as osteomalacia, renal osteodystrophy, and
             hyperparathyroidism.

          4. Patients with unexplained hypocalcemia.

          5. Patients with serum creatinine level of &gt;=200umol/L.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CC Mok</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CC Mok</last_name>
    <phone>852-24685389</phone>
    <email>ccmok2006@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Connie Lo</last_name>
    <phone>852-24685389</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Medicine, Tuen Mun Hospital</name>
      <address>
        <city>Hong Kong</city>
        <zip>000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi Chiu Mok, MD, FRCP</last_name>
      <phone>(852) 2468 5386</phone>
      <email>ccmok2006@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chi Chiu Mok, MD, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2016</study_first_submitted>
  <study_first_submitted_qc>December 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2016</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tuen Mun Hospital</investigator_affiliation>
    <investigator_full_name>Chi Chiu Mok</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>glucocorticoids, steroids, osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

